Breast Cancer - Targeting A Protein Called Cyclin D1 May Block The Expansion Of Cancerous Stem Cells

Main Category: Breast Cancer
Also Included In: Cancer / Oncology
Article Date: 06 Nov 2008 - 1:00 PDT

email to a friend   printer friendly   opinions  

Breast cancer stem cells are known to be involved in therapy resistance and the recurrence of cancerous tumors. A new study appearing in Clinical and Translational Science shows the mechanisms governing stem cell expansion in breast cancer (called Notch activity), and finds that therapy targeting a protein called cyclin D1 may block the expansion of cancerous stem cells.

The study, conducted by Dr. Richard Pestell and colleagues at Thomas Jefferson University, was the first to show that cyclin d1 is required for breast cancer growth in mice. As cyclin d1 is known to be over-expressed in human breast cancer, the findings may explain how cyclin d1 contributes to breast tumor growth, and provide the rationale for targeted therapies at cancerous stem cells in humans.

"Breast and other cancers are maintained through a population of cancer stem cells. By specifically targeting cancer stem cells we hope to reduce recurrence and improve therapy responses," says Pestell.

Cancer arises as a result of the accumulation of multiple genetic lesions that ultimately result in unregulated cell cycle, and Notch activity is a key determinant of the cellular development and differentiation related to this process. As Notch signaling is activated in human breast cancer, (and a negative regulator of Notch signaling reduces the disease), the molecular mechanisms regulating Notch activity are of fundamental importance for future therapy.

To view the abstract for this article, please click here.

Richard G. Pestell Director of the Kimmel Cancer Center at Thomas Jefferson University.

CTS: Clinical and Translational Science is your source for the most current and thought provoking original research across the broad spectrum of clinical specialties and basic science. CTS highlights investigative work bridging the gap between laboratory discovery and practice. CTS will discuss the state-of-the-science and strategies that will accelerate the assimilation of genomics and proteomics information into the clinic. This peer-reviewed journal provides a clear picture of the rich and complex world that is such a part of translational medicine. For information, please visit http://www.blackwell-synergy.com/loi/CTS.

Wiley-Blackwell was formed in February 2007 as a result of the acquisition of Blackwell Publishing Ltd. by John Wiley & Sons, Inc., and its merger with Wiley's Scientific, Technical, and Medical business. Together, the companies have created a global publishing business with deep strength in every major academic and professional field. Wiley-Blackwell publishes approximately 1,400 scholarly peer-reviewed journals and an extensive collection of books with global appeal. For more information on Wiley-Blackwell, please visit http://www.wiley-blackwell.com or http://interscience.wiley.com.

Wiley-Blackwell

• Additional
• References
• Citations